Zepzelca (lurbinectedin)

No conference on lung cancer is complete without a good pun from the one & only @DrSteveMartin 😂 Excellent summary of the activity of lurbinectedin in the 2L setting for patients with SCLC #DAVAHawaiiLung #lcsm (@esinghimd)

"So when you're snorkeling with all the fish and wondering why they don't get SCLC, maybe it's because of the sea squirt!" - @DrSteveMartin delivers a witty and Hawaii-appropriate lecture on the antitumor activity of lurbinectedin in 2L SCLC #DAVAHawaiiLung https://t.co/mK0i1Ni28E (@KE_Gallaway)

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study @CCR_AACR @AACR @OncoAlert https://t.co/13lijTVndA (@VivekSubbiah)

https://t.co/bLP9SKNle9 #zepzelca #pharmamar @PhrmMar @VivekSubbiah "Results and biomarker analyses from these studies and others are eagerly awaited to clearly define the role of #lurbinectedin for the management of neuroendocrine neoplasms beyond #SCLC." @OncoscienceJrnl (@pistoto2017)

@PazAresLab @StephenVLiu @VivekSubbiah @dr_ponce_aix @NarjustFlorezMD @teekayowo @LaurenByersMD @Tony_Calles @sands_jacob @Latinamd May be fyi 👇🏻#sclc #lurbinectedin (@pistoto2017)

Recent Advances in SCLC Treatment - 2022 Program: LCVL https://t.co/IrEotuY3xF via @YouTube In this video, Dr. @StephenVLiu discusses recent drug advances for SCLC, including Lurbinectedin, Tarlatamab, and the antibody-drug conjugate DS-7300. (@cancerGRACE)

European Commission grants #OrphanDrug designation to #PharmaMars #Lurbinectedin for the treatment of #SoftTissueSarcoma $PHM https://t.co/jZgw2c3SiW (@1stOncology)

Abstracts of #lurbinectedin in the next ASCO conference #ASCO2023 #zepzelca #pharmamar #sclc #leiomyosarcoma (@pistoto2017)

"Lurbinectedin is not only safe and effective but is also cost-effective in the care of patients with relapsed #SCLC," said @AparGanti MD, MS. #ISPOR23 | @ISPORorg @unmc https://t.co/pEOyH3TzZO (@TargetedOnc)

Dr. @NouraChoudhury with a great overview of #SCLC at #OncLiveSOSS. Chemo-IO is our accepted 1L SOC. Ongoing investigation in lurbinectedin maintenance, salvage tarlatamab, and B7H3 ADCs like I-DxD offer reason for optimism. #LCSM (@StephenVLiu)

Up to date overview of #SCLC management at #PLCClive23 from Dr. @JennyCarlisleMD. Standard 1L remains atezolizumab or durvalumab with platinum + etoposide. Salvage options are lurbinectedin, topotecan. #EGFR transformed to SCLC is a different disease in need of better options. (@StephenVLiu)

🧬🎯Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study 1/4 @myESMO @ESMO_Open @oncoalert #bcsm https://t.co/BpbrRNURx1 (@VivekSubbiah)

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study @ESMO_Open @myESMO https://t.co/V9nZ5SSKoi (@VivekSubbiah)

⭐️Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study #BCSM @myESMO @ESMO_Open @OncoAlert @weoncologists Open access link: https://t.co/O2RjbqO1cG (@VivekSubbiah)

The current efficacy results in patients with germline BRCA-mutated metastatic breast cancer show lurbinectedin as an active and safe agent in this population, especially in patients with BRCA2 mutations. These results are in line with findings in a previous phase II trial. (@pistoto2017)

#Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline #BRCA1/2 metastatic breast cancer #mBC: results from a #phaseII basket study @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/dC0PuxFXpY (@ESMO_Open)

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study https://t.co/M3FOwYB9cH (@VivekSubbiah)

In preclinical models it was shown that lurbinectedin is effective in suppressing the activity of the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus and delayed tumor growth in mice bearing Ewing sarcoma xenografts. https://t.co/9GuHlsaZvv (@VivekSubbiah)

⭐️Open access article now available online 👉Lurbinectedin -Selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic #breastcancer: results from a phase II basket study @OncoAlert @myESMO @ESMO_Open #ESMO22 https://t.co/C9rwbE24rn (@VivekSubbiah)

⭐️Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study #bcsm @OncoAlert @weoncologists @myESMO @ESMO_Open https://t.co/YzOc52lMSa (@VivekSubbiah)

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study https://t.co/xH0pul149I (@VivekSubbiah)

Lurbinectedin, selective inhibitor of oncogenic transcription, in patients with germline BRCA1/2 metastatic #breastcancer #BCSM ✅ORR = 28.6%; ✅PR=4 /11 pts (36.4%)- BRCA2 ✅PR=2/10 pts (20.0%)- BRCA1 @ESMO_Open @myESMO @oncoalert https://t.co/C1uraGvDG9 (@VivekSubbiah)

Thank you @jamecancerdoc ! This drug is FDA approved for small cell lung cancer & is active in Ewing sarcoma & now BRCA1/2 breast cancers. Lurbinectedin as second-line treatment for patients with small-cell lung cancer https://t.co/UEt464ZHHR (@VivekSubbiah)

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study #bcsm @ESMO_Open @myESMO @OncoAlert 🚨 https://t.co/xdRij7JXlh (@VivekSubbiah)

🚨Hot off the press👉 #SundayMorning reading 👉Lurbinectedin, selective inhibitor of oncogenic transcription, in patients with germline BRCA1/2 metastatic #breastcancer: results from a phase II basket study #BCSM @ESMO_Open @myESMO @oncoalert https://t.co/Du8NecR979 (@VivekSubbiah)

🚨Hot off the press👉Lurbinectedin, selective inhibitor of oncogenic transcription, in patients with germline BRCA1/2 metastatic #breastcancer #BCSM ✅ORR = 28.6%; ✅PR=4 /11 pts (36.4%)- BRCA2 ✅PR=2/10 pts (20.0%)- BRCA1 @ESMO_Open @myESMO @oncoalert https://t.co/Du8NecR979 (@VivekSubbiah)

In pre-clinical models it was shown that lurbinectedin is effective in suppressing the activity of the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus and delayed tumor growth in mice bearing Ewing sarcoma xenografts https://t.co/Rk4LY3e10g (@VivekSubbiah)

Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. https://t.co/OFobpmO4v5 (@VivekSubbiah)

Hear Ye, hear Ye!! FDA Accelerates Approval of Lurbinectedin in Metastatic Small Cell Lung Cancer. Decreases transcription of IL6, IL8, CCL2 and VEGF https://t.co/oixEDwOE89 (@Dr_R_Kurzrock)

.@JackWestMD, MD, a thoracic oncologist from @Swedish, discusses the emerging agent #lurbinectedin in the small cell #lungcancer (#SCLC) landscape. #ASCO18 @ASCO https://t.co/0UhtHnrp0s (@PhrmMar)

#ASCO18 Estos son los abstracts que presentará #PharmaMar durante la jornada de hoy #BCSM #Liposarcoma #Leiomysarcoma #Sarcoma #STS #EwingSarcoma en @ASCO #Lurbinectedina #Trabectedina #AvancesPharmaMar 📌 Abstracts Info: https://t.co/XQbAGfpuov (@PhrmMar)

#PharmaMar Announces Data Presentations For Both Its #Molecules #Yondelis and #Lurbinectedin at @ASCO https://t.co/zl8GgbwYvF @fwpharma @PhrmMar #lurbinectedin #PM1183 #plitidepsin #pharma #trabectedin #sarcoma (@PlexusVentures)